278790-00-4

Usage

Uses

Used in Pharmaceutical Research:
(R)-N-1-BOC-4-CBZ-2-PIPERAZINECARBOXYLIC ACID METHYL ESTER is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its versatile reactivity and the presence of protective groups. The BOC and CBZ groups allow for selective deprotection of amine groups, enabling the synthesis of complex molecules with specific functionalities.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-N-1-BOC-4-CBZ-2-PIPERAZINECARBOXYLIC ACID METHYL ESTER serves as a building block for the creation of a wide range of organic compounds. Its unique structure and functional groups facilitate the formation of new chemical bonds and the synthesis of target molecules with desired properties.
Used in Drug Discovery:
(R)-N-1-BOC-4-CBZ-2-PIPERAZINECARBOXYLIC ACID METHYL ESTER is used as a starting material in drug discovery for the development of new therapeutic agents. The biological activity of the piperazine ring structure makes it a promising candidate for the design of novel drugs with potential applications in various medical fields.
Used in the Synthesis of Piperazine-Derived Compounds:
In the chemical industry, (R)-N-1-BOC-4-CBZ-2-PIPERAZINECARBOXYLIC ACID METHYL ESTER is used as a precursor for the synthesis of piperazine-derived compounds, which have a wide range of applications, including as pharmaceuticals, agrochemicals, and other specialty chemicals. (R)-N-1-BOC-4-CBZ-2-PIPERAZINECARBOXYLIC ACID METHYL ESTER's unique structure and functional groups enable the synthesis of diverse piperazine derivatives with tailored properties for specific applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 405175-79-3 (R)-4-((benzyloxy)carbonyl)piperazine-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 138775-02-7 (2R)-4-[(benzyloxy)carbonyl]-1-[(tert-butoxy)carbonyl]piperazine-2-carboxylic acid 
• 126330-91-4 Methyl (R)-6-oxopiperazine-2-carboxylate 
• 501-53-1 benzyl chloroformate 
• 126330-92-5 3-amino-N-[(benzyloxy)carbonyl]-D-alanine methyl ester 

Downstream Products

• 279227-92-8 (R)-1-N-Boc-piperazine-2-carboxylic acid methyl ester hydrochloride 

Relevant academic research and scientific papers

NOVEL FARNESYL PROTEIN TRANSFERASE INHIBITORS AND THEIR USE TO TREAT CANCER

Disclosed are compounds of the formula: wherein R8 represents a cyclic and acyclic moiety to which is bound an imidazolylalkyl group; R9 represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also d

Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308

Although intravenously administered antiplatelet fibrinogen receptor (GPIIb/IIIa) antagonists have become established in the acute-care clinical setting for the prevention of thrombosis, orally administered drugs for chronic use are still under development. Herein, we present details from our exploration of structure-activity surrounding the prototype fibrinogen receptor antagonist RWJ-50042 (racemate of 1), which was derived from a unique approach involving the γ-chain of fibrinogen (Hoekstra et al. J. Med. Chem. 1995, 38, 1582). Our analogue studies culminated in the discovery of RWJ-53308 (2), a potent, orally active GPIIb/IIIa antagonist. To progress from RWJ-50042 to a suitable candidate for clinical development, we conducted a series of optimization cycles that employed solid-phase parallel synthesis for the rapid, efficient preparation of nearly 250 analogues, which were assayed for fibrinogen receptor affinity and inhibition of platelet aggregation induced by four different activators. This strategy produced several promising analogues for advanced study, including 3-(3,4- methylenedioxybenzene)-β-amino acid analogue 3 (significant improved in vivo potency) and 3-(3-pyridyl)-β-amino acid 2 (significantly improved potency, oral absorption, and duration of action). In dogs, 2 displayed significant ex vivo antiplatelet activity on oral administration at 1.0 mg/kg, 16% systemic oral bioavailability, minimal metabolic transformation, and an excellent safety profile. Additionally, 2 was found to be efficacious in three in vivo thrombosis models: canine arteriovenous (AV) shunt (0.01-0.1 mg/kg, iv), guinea pig photoactivation-induced injury (0.3-3 mg/kg, iv), and guinea pig ferric chloride-induced injury (0.3-1 mg/kg, iv). On the basis of its noteworthy preclinical data, RWJ-53308 (2) was selected for clinical evaluation.